[{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Delpharm Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Creapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ AzurRx","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ AzurRx"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Private Placement","leadProduct":"MS1819","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Yeast recombinant lipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Yeast recombinant lipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"PPD","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Niclosamide","moa":"SARS-CoV-2 spike protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"immediate-release Capsule","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Enteric capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"PPD","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"Wnt signaling","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"oral immediate-release tablet","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Yeast Recombinant Lipase","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"SARS-CoV-2 spike protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.23000000000000001,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ AzurRx","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ AzurRx"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase Alfa","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Pace Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Pace Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Pace Life Sciences"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase Alfa","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"First Wave BioPharma \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"First Wave BioPharma \/ First Wave BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"ImmunogenX","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"First Wave BioPharma \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ First Wave BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"ImmunogenX","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"First Wave BioPharma \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ First Wave BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Niclosamide","moa":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by First Wave BioPharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
